Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
21 studies found for:    brca | Open Studies | United States, Massachusetts

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
2 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
3 Recruiting A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Placebo
4 Recruiting Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
Conditions: Advanced Malignant Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Solid Neoplasm
Interventions: Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
5 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
6 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
7 Recruiting A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Conditions: Carcinoma of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation
Interventions: Drug: niraparib;   Drug: Physician's choice
8 Recruiting Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Conditions: Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention;   Other: educational intervention;   Other: survey administration;   Behavioral: psychosocial assessment and care;   Behavioral: supportive care
9 Recruiting Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.
Condition: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: Drug: OLAPARIB;   Drug: Single agent chemotherapy
10 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
11 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
12 Recruiting Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
13 Recruiting Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Conditions: Germline BRCA1/2 Mutations and;   Metastatic Adenocarcinoma of the Pancreas
Interventions: Drug: Olaparib;   Drug: Placebo
14 Recruiting HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Condition: Breast Cancer
Interventions: Drug: HKI-272;   Procedure: Surgical Resection;   Drug: Capecitabine
15 Recruiting The Cancer of the Pancreas Screening-5 CAPS5)Study
Conditions: Pancreas Cancer;   Peutz-Jeghers Syndrome;   Gene Mutation;   Germline Mutation Carrier;   Lynch Syndrome
Intervention: Drug: Human synthetic secretin
16 Recruiting Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasm
Interventions: Other: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel
17 Recruiting A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Condition: Ovarian Cancer
Intervention: Drug: Niraparib
18 Recruiting Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: lurbinectedin (PM01183)
19 Not yet recruiting A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Condition: Advanced Cancers
Intervention: Drug: LY2606368
20 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
To Top

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
† Indicates status has not been verified in more than two years